RDRajiv Devanagondi

Rajiv Devanagondi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rajiv Devanagondi has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Association of Pre-Fontan Hemodynamics With Long-Term Outcomes After Fontan Palliation: A Study From the Pediatric Cardiac Care Consortium

    by Divya Suthar, Yanxu Yang, Asaad G. Beshish, Jessica Knight, Xiao Song, Amanda Thomas, Hua Hao, Fawwaz R. Shaw, Kathy Jenkins, Jeffrey P. Jacobs, et al.

    BACKGROUND: Long-term outcomes after Fontan vary widely. Although pre-Fontan hemodynamics predict early failure, their association with long-term outcomes remains unclear. We hypothesized that pre-Fontan hemodynamics predict long-term risk of death or transplantation. METHODS: We analyzed data from the Pediatric Cardiac Care Consortium, a US-based multicenter registry including patients undergoing first-time Fontan with pre-Fontan catheterization and long-term follow-up. Patients undergoing a Fontan procedure before 18 years of age at any time between 1982 and 2011 were included in the study. Outcomes of interest were in-hospital Fontan failure (death or takedown) and postdischarge death or transplantation, identified through matching with the National Death Index and the Organ Procurement and Transplantation Network through 2022. Associations between pre-Fontan hemodynamics and long-term risk for death or transplantation were assessed with Kaplan-Meier survival curves and extended Cox regression. RESULTS: Among 1175 patients (736 [62.6%] male, 626 [53.3%] with systemic left ventricle), 1111 were discharged with Fontan physiology. Over a median postdischarge follow-up of 20.6 years (interquartile range, 18.2–24.4 years), 85 deaths and 49 transplantations occurred. Pre-Fontan mean pulmonary arterial pressure was the strongest hemodynamic predictor of postdischarge outcomes with a continuous association and no clear inflection point; 25-year transplantation-free survival declined from 83.7% (95% CI, 77.6–88.3) in the low mean pulmonary arterial pressure tertile to 73.7% (95% CI, 65.5–80.3) in the highest tertile (log-rank P =0.02). Each 1-SD increase in mean pulmonary arterial pressure was associated with 1.33-fold higher odds of in-hospital failure (adjusted odds ratio, 1.33 [95% CI, 1.00–1.77]; P =0.05) and a 2.2-fold higher hazard of death or transplantation (adjusted hazard ratio, 2.20 [95% CI, 1.62–3.00]; P P P 4 years of age versus 2 to 4 years of age; adjusted hazard ratio, 1.80 [95% CI, 1.25–2.60]; P =0.02). CONCLUSIONS: Elevated pre-Fontan mean pulmonary arterial pressure is a strong predictor of in-hospital and long-term post-Fontan risk of death or transplantation. Systemic right ventricle and delayed Fontan completion (>4 years of age) further increased risk. These findings support early Fontan consideration and ongoing hemodynamic surveillance to optimize long-term outcomes.


  • Open Access

    Right Ventricle Myxoma Masquerading as a Thrombus in a Pediatric Patient

    by Nikhila Rao, Nilesh Rao, George Alfieris, Christopher Prendergast, Rajiv Devanagondi

  • Open Access

    A Case of Complete Functional Myocardial Regeneration in a Human Neonate

    by Jyoti Gur, Rajiv Devanagondi, Rebecca Pratt, Frank Smith, Jason Mandell, Susan Martin, George A. Porter


  • Hybrid Versus Percutaneous Left Atrial Decompression in Infants With Hypoplastic Left Heart Variants and an Intact or Highly Restrictive Atrial Septum: A Multicenter PICES Study

    by Konstantin Averin, Michael D. Seckeler, Holly Bauser-Heaton, Matthew C. Schwartz, Paul Tannous, Cameron Seaman, Wendy Whiteside, George T. Nicholson, Priti M. Patel, Brent M. Gordon, et al.

    BACKGROUND: Neonates with hypoplastic left heart syndrome variants with an intact or highly restrictive atrial septum (HLH-IAS) require immediate postnatal intervention to survive. Emergent left atrial decompression (LAD) via a percutaneous or hybrid approach is standard, but the comparative effectiveness and outcomes of these approaches remain underexplored. METHODS: A multicenter retrospective analysis of all neonates with HLH-IAS who underwent LAD in the first 36 hours of life from January 2009 to March 2020 at 14 North American congenital cardiac programs was conducted. Patient and procedural characteristics and patient outcomes were compared between hybrid and percutaneous LAD. RESULTS: Among 128 patients with HLH-IAS, 105 (80%) underwent percutaneous LAD and 23 (17%) hybrid LAD. No significant differences were observed in preprocedural characteristics such as birth weight (3.1±0.6 versus 3.2±0.6 kg; P =0.453), presence of a baseline interatrial communication (66% versus 61%; P =0.659), interatrial communication gradient (14.4±6.9 versus 12.7±4.6 mm Hg; P =0.456), or lowest pH (7.13±0.14 versus 7.09±0.15; P =0.193). Hybrid LAD resulted in a shorter time from birth to procedure (120 versus 52 minutes; P =0.005) and to atrial septal defect creation (55 versus 29 minutes; P =0.002). All hybrid LAD were technically successful, although 11 (10%) percutaneous LAD were unsuccessful with 7 requiring conversion to surgical septectomy. There was a trend toward fewer serious adverse events with hybrid LAD (36% versus 17%; P =0.141). Most patients (67%) who underwent hybrid LAD had simultaneous pulmonary artery band placement and 21% of patients with percutaneous LAD required reoperation for pulmonary artery band. Long-term survival rates were comparably low between groups, with a 30% transplant-free survival at a median 8-month follow-up. CONCLUSIONS: In patients with HLH-IAS, hybrid LAD allows for faster atrial septal defect creation, has a higher technical success rate, and potentially fewer procedural serious adverse events compared with percutaneous LAD, alongside facilitating simultaneous pulmonary artery band. Our findings underscore the poor prognosis for patients with HLH-IAS despite intervention, highlighting the need for better treatment strategies.


  • New-Onset Anasarca in a Previously Healthy 10-year-old

    by Danielle Ackley, Luke Eastburg, Rajiv Devanagondi

  • Transcatheter Fontan Fenestration Closure: Sustained Improvements in Oxygen Saturation with Minimal Morbidity and Mortality

    by Rajiv Devanagondi, Glenn Leonard

    Fontan fenestration decreases central venous pressure and preserves cardiac output while decreasing systemic oxygen saturation. Transcatheter fenestration closure increases oxygen saturation, though the persistence of this increase and the long-term incidence of adverse outcomes such as death and heart transplant remain unknown. We describe immediate and long-term clinical and adverse outcomes following fenestration closure. Catheterization, echocardiogram, and clinic reports were reviewed following transcatheter Fontan fenestration closure. Data were reported as n (%) and median (IQR). Continuous variables were compared using Wilcoxon ranked sum test. 51 patients had fenestration closure 0.9 (0.7–1.5) years following extracardiac Fontan operation. Most (84%) were closed with Amplatzer Septal Occluders. Systemic O2 saturation immediately increased from 87 (83–89) to 95 (94–97)%, P < 0.05. Cardiac index decreased from 4 (3–5) to 2.9 (2.6–3.5) L/min/m2. Fontan pressure and pulmonary vascular resistance were not significantly changed. Clinical follow-up duration for all patients was 7.3 (range 1.3–16) years. Oxygen saturation at last follow-up was 94.5 (92–97)% and did not decrease over time (P < 0.05). One patient (2%) developed protein losing enteropathy, 1 (2%) had heart transplant, and 1 (2%) patient died 9.4 years following fenestration closure. No patient required fenestration re-creation following closure. Transcatheter Fontan fenestration closure leads to sustained increases in systemic oxygen saturation and a low incidence of adverse outcomes such as death and transplant. Further study comparing fenestration closure to non-closure and longer follow-up duration are required to determine if there is a survival benefit to fenestration closure.


  • Open Access

    Transcatheter Fontan fenestration closure: sustained improvements in oxygen saturation with minimal morbidity and mortality

    by Rajiv Devanagondi, Glenn Leonard

    Background: Fontan fenestration decreases central venous pressure and preserves cardiac output while decreasing systemic oxygen saturation. Transcatheter fenestration closure increases oxygen saturation, though the persistence of this increase and the long-term incidence of adverse outcomes such as death and heart transplant remain unknown. We describe immediate and long-term clinical and adverse outcomes following fenestration closure. Methods: Catheterization, echocardiogram, and clinic reports were reviewed following transcatheter Fontan fenestration closure. Data were reported as n (%) and median (IQR). Continuous variables were compared using Wilcoxon ranked sum test. Results: 51 patients had fenestration closure 0.9 (0.7–1.5) years following extra-cardiac Fontan operation. Most (84%) were closed with Amplatzer Septal Occluders. Systemic O2 saturation immediately increased from 87 (83–89)% to 95 (94–97)%, p < 0.05. Cardiac index decreased from 4 (3–5) to 2.9 (2.6–3.5) L/min/m2. Fontan pressure and pulmonary vascular resistance were not significantly changed. Clinical follow up duration for all patients was 7.3 (range 1.3–16) years. Oxygen saturation at last follow up was 94.5 (92–97)% and did not decrease over time (p < 0.05). One patient (2%) developed protein losing enteropathy, 1 (2%) had heart transplant, and 1 (2%) patient died 9.4 years following fenestration closure. No patient required fenestration re-creation following closure. Conclusions: Transcatheter Fontan fenestration closure leads to sustained increases in systemic oxygen saturation and a low incidence of adverse outcomes such as death and transplant. Further study comparing fenestration closure to non-closure and longer follow up duration are required to determine if there is a survival benefit to fenestration closure.

  • Long-Term Outcomes of Balloon Valvuloplasty for Isolated Pulmonary Valve Stenosis

    by Rajiv Devanagondi, Dan Peck, Janaki Sagi, Janet Donohue, Sunkyung Yu, Sara K. Pasquali, Aimee K. Armstrong

    To evaluate the long-term cumulative incidence of ≥ moderate pulmonary regurgitation (PR) and re-intervention following balloon pulmonary valvuloplasty (BPV). While BPV for pulmonary valve stenosis (PS) relieves obstruction acutely, long-term outcomes are not well documented. Between 1982 and 2002, 211 patients had BPV for isolated PS. Follow-up data were available for 103 patients. Cumulative incidence of ≥ moderate PR and re-intervention was evaluated and risk factors for ≥ moderate PR assessed in univariate and multivariable analyses. Median age at BPV was 0.7 years (range 1 day–42.2 years); peak catheter gradient was 65 mmHg (range 31–169 mmHg); 23% had critical PS. Sixty-two patients had a recent echocardiogram with median follow-up 15.1 years (range 10.1–26.3 years); 60% had ≥ moderate PR. Three patients had pulmonary valve replacement following BPV due to symptomatic severe PR. In univariate analysis, critical PS, younger age, smaller BSA, and smaller pulmonary annulus at the time of BPV, as well as greater baseline PS gradient by catheterization, were associated with ≥ moderate PR (all p < 0.05). In multivariable analysis, only BSA < 0.3 m2 was independently associated with ≥ moderate PR (adjusted odds ratio 6.4, 95% confidence interval 1.2–33.6). In the largest study to date of > 10-year outcomes following BPV, 60% of patients with available follow-up data developed ≥ moderate PR. Few patients had pulmonary valve replacement. Patients with lower BSA at the time of BPV were more likely to have greater PR at late follow-up.


  • Protein Losing Enteropathy After Cardiac Transplantation Successfully Treated by Stent Implantation

    by Rajiv Devanagondi, Patcharapong Suntharos, Gerard J. Boyle, Lourdes R. Prieto

    Protein losing enteropathy (PLE) is a severe consequence of Fontan physiology that sometimes requires heart transplantation for definitive treatment. We describe transplant refractory PLE in a patient with heterotaxia and complex systemic and hepatic venous connections, successfully treated by transcatheter relief of multiple venous obstructions.


  • Results of coil closure of patent ductus arteriosus using a tapered tip catheter for enhanced control

    by Rajiv Devanagondi, Larry Latson, Sharon Bradley-Skelton, Lourdes Prieto